Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 397 to 405 of 405 entries
Sorted by: Best Match Show Resources per page
Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection.

medRxiv : the preprint server for health sciences

Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK.
PMID: 35018382
medRxiv. 2021 Dec 30; doi: 10.1101/2021.12.25.21268211.

Monoclonal antibodies (mAbs) are the treatment of choice for high-risk ambulatory persons with mild to moderate COVID-19. We studied viral culture dynamics post-treatment in a subset of participants receiving the mAb bamlanivimab in the ACTIV-2 trial. Viral load by...

Cite
Boucau J, Chew KW, Choudhary M, et al. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv. 2021;doi: 10.1101/2021.12.25.21268211.
Boucau, J., Chew, K. W., Choudhary, M., Deo, R., Regan, J., Flynn, J. P., Crain, C. R., Hughes, M. D., Ritz, J., Moser, C., Dragavon, J. A., Javan, A. C., Nirula, A., Klekotka, P., Greninger, A. L., Coombs, R. W., Fischer, W. A., Daar, E. S., Wohl, D. A., Eron, J. J., Currier, J. S., Smith, D. M., Li, J. Z., Barczak, A. K. (2021). Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv : the preprint server for health sciences, . https://doi.org/10.1101/2021.12.25.21268211
Boucau, Julie, et al. "Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection." medRxiv : the preprint server for health sciences vol. (2021). doi: https://doi.org/10.1101/2021.12.25.21268211
Boucau J, Chew KW, Choudhary M, Deo R, Regan J, Flynn JP, Crain CR, Hughes MD, Ritz J, Moser C, Dragavon JA, Javan AC, Nirula A, Klekotka P, Greninger AL, Coombs RW, Fischer WA, Daar ES, Wohl DA, Eron JJ, Currier JS, Smith DM, Li JZ, Barczak AK. Monoclonal antibody treatment drives rapid culture conversion in SARS-CoV-2 infection. medRxiv. 2021 Dec 30; doi: 10.1101/2021.12.25.21268211. PMID: 35018382; PMCID: PMC8750705.
Copy Download .nbib Format: NLM
Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer.

Lung cancer (Amsterdam, Netherlands)

Huicochea Castellanos S, Pagano A, Plodkowski AJ, Girshman J, Hellmann MD, Rizvi H, Flynn J, Zheng J, Capanu M, Halpenny DF, Ginsberg MS.
PMID: 34536733
Lung Cancer. 2021 Nov;161:60-67. doi: 10.1016/j.lungcan.2021.08.020. Epub 2021 Sep 04.

OBJECTIVES: To investigate the inter- and intra-reader agreement of immune Response Evaluation Criteria in Solid Tumors (iRECIST) and Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) in patients with lung cancer treated with immunotherapy.MATERIALS AND METHODS: This...

Cite
Huicochea Castellanos S, Pagano A, Plodkowski AJ, et al. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung Cancer. 2021;161:60-67doi: 10.1016/j.lungcan.2021.08.020.
Huicochea Castellanos, S., Pagano, A., Plodkowski, A. J., Girshman, J., Hellmann, M. D., Rizvi, H., Flynn, J., Zheng, J., Capanu, M., Halpenny, D. F., & Ginsberg, M. S. (2021). Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung cancer (Amsterdam, Netherlands), 16160-67. https://doi.org/10.1016/j.lungcan.2021.08.020
Huicochea Castellanos, Sandra, et al. "Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer." Lung cancer (Amsterdam, Netherlands) vol. 161 (2021): 60-67. doi: https://doi.org/10.1016/j.lungcan.2021.08.020
Huicochea Castellanos S, Pagano A, Plodkowski AJ, Girshman J, Hellmann MD, Rizvi H, Flynn J, Zheng J, Capanu M, Halpenny DF, Ginsberg MS. Intra- and inter-reader agreement of iRECIST and RECIST 1.1 criteria for the assessment of tumor response in patients receiving checkpoint inhibitor immunotherapy for lung cancer. Lung Cancer. 2021 Nov;161:60-67. doi: 10.1016/j.lungcan.2021.08.020. Epub 2021 Sep 04. PMID: 34536733.
Copy Download .nbib Format: NLM
Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates.

bioRxiv : the preprint server for biology

S Arunachalam P, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Roltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Doyle-Meyer L, Bohm RB, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O Hagan DT, Most RV, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar M, King NP, Veesler D, Pulendran B.
PMID: 33594366
bioRxiv. 2021 Feb 11; doi: 10.1101/2021.02.10.430696.

The development of a portfolio of SARS-CoV-2 vaccines to vaccinate the global population remains an urgent public health imperative. Here, we demonstrate the capacity of a subunit vaccine under clinical development, comprising the SARS-CoV-2 Spike protein receptor-binding domain displayed...

Cite
S Arunachalam P, Walls AC, Golden N, et al. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv. 2021;doi: 10.1101/2021.02.10.430696.
S Arunachalam, P., Walls, A. C., Golden, N., Atyeo, C., Fischinger, S., Li, C., Aye, P., Navarro, M. J., Lai, L., Edara, V. V., Roltgen, K., Rogers, K., Shirreff, L., Ferrell, D. E., Wrenn, S., Pettie, D., Kraft, J. C., Miranda, M. C., Kepl, E., Sydeman, C., Brunette, N., Murphy, M., Fiala, B., Carter, L., White, A. G., Trisal, M., Hsieh, C. L., Russell-Lodrigue, K., Monjure, C., Dufour, J., Doyle-Meyer, L., Bohm, R. B., Maness, N. J., Roy, C., Plante, J. A., Plante, K. S., Zhu, A., Gorman, M. J., Shin, S., Shen, X., Fontenot, J., Gupta, S., O Hagan, D. T., Most, R. V., Rappuoli, R., Coffman, R. L., Novack, D., McLellan, J. S., Subramaniam, S., Montefiori, D., Boyd, S. D., Flynn, J. L., Alter, G., Villinger, F., Kleanthous, H., Rappaport, J., Suthar, M., King, N. P., Veesler, D., & Pulendran, B. (2021). Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv : the preprint server for biology, . https://doi.org/10.1101/2021.02.10.430696
S Arunachalam, Prabhu, et al. "Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates." bioRxiv : the preprint server for biology vol. (2021). doi: https://doi.org/10.1101/2021.02.10.430696
S Arunachalam P, Walls AC, Golden N, Atyeo C, Fischinger S, Li C, Aye P, Navarro MJ, Lai L, Edara VV, Roltgen K, Rogers K, Shirreff L, Ferrell DE, Wrenn S, Pettie D, Kraft JC, Miranda MC, Kepl E, Sydeman C, Brunette N, Murphy M, Fiala B, Carter L, White AG, Trisal M, Hsieh CL, Russell-Lodrigue K, Monjure C, Dufour J, Doyle-Meyer L, Bohm RB, Maness NJ, Roy C, Plante JA, Plante KS, Zhu A, Gorman MJ, Shin S, Shen X, Fontenot J, Gupta S, O Hagan DT, Most RV, Rappuoli R, Coffman RL, Novack D, McLellan JS, Subramaniam S, Montefiori D, Boyd SD, Flynn JL, Alter G, Villinger F, Kleanthous H, Rappaport J, Suthar M, King NP, Veesler D, Pulendran B. Adjuvanting a subunit SARS-CoV-2 nanoparticle vaccine to induce protective immunity in non-human primates. bioRxiv. 2021 Feb 11; doi: 10.1101/2021.02.10.430696. PMID: 33594366; PMCID: PMC7885918.
Copy Download .nbib Format: NLM
The identification of needs and development of best practice guidance for the psychological support of frontline healthcare workers during and after COVID-19: A protocol for the FLoWS project.

HRB open research

Flynn J, O'Connor L, Hanlon M, Bellani G, Contreras M, Doherty A, Durand H, Fallon E, Gormley C, Laffey J, Molloy G, Sarma K, Strepparava MG, Russo S, Walsh J, McGuire BE.
PMID: 33870088
HRB Open Res. 2021 Jan 29;3:54. doi: 10.12688/hrbopenres.13117.2. eCollection 2020.

Recent estimates suggest that up to 34% of frontline workers in healthcare (FLWs) at the forefront of the COVID-19 pandemic response are reporting elevated symptoms of psychological distress due to resource constraints, ineffective treatments, and concerns about self-contamination. However,...

Cite
Flynn J, O'Connor L, Hanlon M, et al. The identification of needs and development of best practice guidance for the psychological support of frontline healthcare workers during and after COVID-19: A protocol for the FLoWS project. HRB Open Res. 2021;3:54doi: 10.12688/hrbopenres.13117.2.
Flynn, J., O'Connor, L., Hanlon, M., Bellani, G., Contreras, M., Doherty, A., Durand, H., Fallon, E., Gormley, C., Laffey, J., Molloy, G., Sarma, K., Strepparava, M. G., Russo, S., Walsh, J., & McGuire, B. E. (2020). The identification of needs and development of best practice guidance for the psychological support of frontline healthcare workers during and after COVID-19: A protocol for the FLoWS project. HRB open research, 354. https://doi.org/10.12688/hrbopenres.13117.2
Flynn, Jack, et al. "The identification of needs and development of best practice guidance for the psychological support of frontline healthcare workers during and after COVID-19: A protocol for the FLoWS project." HRB open research vol. 3 (2020): 54. doi: https://doi.org/10.12688/hrbopenres.13117.2
Flynn J, O'Connor L, Hanlon M, Bellani G, Contreras M, Doherty A, Durand H, Fallon E, Gormley C, Laffey J, Molloy G, Sarma K, Strepparava MG, Russo S, Walsh J, McGuire BE. The identification of needs and development of best practice guidance for the psychological support of frontline healthcare workers during and after COVID-19: A protocol for the FLoWS project. HRB Open Res. 2021 Jan 29;3:54. doi: 10.12688/hrbopenres.13117.2. eCollection 2020. PMID: 33870088; PMCID: PMC8030118.
Copy Download .nbib Format: NLM
Modifiable early life exposures associated with adiposity and obesity in 3-year old children born to mothers with obesity.

Pediatric obesity

Dalrymple KV, Flynn AC, Seed PT, Briley AL, O'Keeffe M, Godfrey KM, Poston L.
PMID: 33998777
Pediatr Obes. 2021 Nov;16(11):e12801. doi: 10.1111/ijpo.12801. Epub 2021 May 17.

BACKGROUND: Children born to mothers with obesity are at increased risk of obesity. Influences underlying this predisposition include in-utero exposures, genetic predisposition and a shared family environment. Effective intervention strategies are needed to prevent obesity in these high-risk children;...

Cite
Dalrymple KV, Flynn AC, Seed PT, et al. Modifiable early life exposures associated with adiposity and obesity in 3-year old children born to mothers with obesity. Pediatr Obes. 2021;16(11):e12801doi: 10.1111/ijpo.12801.
Dalrymple, K. V., Flynn, A. C., Seed, P. T., Briley, A. L., O'Keeffe, M., Godfrey, K. M., Poston, L. (2021). Modifiable early life exposures associated with adiposity and obesity in 3-year old children born to mothers with obesity. Pediatric obesity, 16(11), e12801. https://doi.org/10.1111/ijpo.12801
Dalrymple, Kathryn V, et al. "Modifiable early life exposures associated with adiposity and obesity in 3-year old children born to mothers with obesity." Pediatric obesity vol. 16,11 (2021): e12801. doi: https://doi.org/10.1111/ijpo.12801
Dalrymple KV, Flynn AC, Seed PT, Briley AL, O'Keeffe M, Godfrey KM, Poston L. Modifiable early life exposures associated with adiposity and obesity in 3-year old children born to mothers with obesity. Pediatr Obes. 2021 Nov;16(11):e12801. doi: 10.1111/ijpo.12801. Epub 2021 May 17. PMID: 33998777; PMCID: PMC7611818.
Copy Download .nbib Format: NLM
Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial.

The Lancet. Child & adolescent health

Landier W, Bhatia S, Wong FL, York JM, Flynn JS, Henneberg HM, Singh P, Adams K, Wasilewski-Masker K, Cherven B, Jasty-Rao R, Leonard M, Connelly JA, Armenian SH, Robison LL, Giuliano AR, Hudson MM, Klosky JL.
PMID: 34767765
Lancet Child Adolesc Health. 2022 Jan;6(1):38-48. doi: 10.1016/S2352-4642(21)00278-9. Epub 2021 Nov 10.

BACKGROUND: Young survivors of cancer are at increased risk for cancers that are related to human papillomavirus (HPV), primarily caused by oncogenic HPV types 16 and 18. We aimed to examine the immunogenicity and safety of the three-dose series...

Cite
Landier W, Bhatia S, Wong FL, et al. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. Lancet Child Adolesc Health. 2021;6(1):38-48doi: 10.1016/S2352-4642(21)00278-9.
Landier, W., Bhatia, S., Wong, F. L., York, J. M., Flynn, J. S., Henneberg, H. M., Singh, P., Adams, K., Wasilewski-Masker, K., Cherven, B., Jasty-Rao, R., Leonard, M., Connelly, J. A., Armenian, S. H., Robison, L. L., Giuliano, A. R., Hudson, M. M., & Klosky, J. L. (2022). Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. The Lancet. Child & adolescent health, 6(1), 38-48. https://doi.org/10.1016/S2352-4642(21)00278-9
Landier, Wendy, et al. "Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial." The Lancet. Child & adolescent health vol. 6,1 (2022): 38-48. doi: https://doi.org/10.1016/S2352-4642(21)00278-9
Landier W, Bhatia S, Wong FL, York JM, Flynn JS, Henneberg HM, Singh P, Adams K, Wasilewski-Masker K, Cherven B, Jasty-Rao R, Leonard M, Connelly JA, Armenian SH, Robison LL, Giuliano AR, Hudson MM, Klosky JL. Immunogenicity and safety of the human papillomavirus vaccine in young survivors of cancer in the USA: a single-arm, open-label, phase 2, non-inferiority trial. Lancet Child Adolesc Health. 2022 Jan;6(1):38-48. doi: 10.1016/S2352-4642(21)00278-9. Epub 2021 Nov 10. PMID: 34767765.
Copy Download .nbib Format: NLM
Luminal microvesicles uniquely influence translocating bacteria after SIV infection.

Mucosal immunology

Flynn JK, Langner CA, Karmele EP, Baker PJ, Pei L, Gorfu EG, Bochart RM, Santiana M, Smelkinson MG, Nutman TB, Altan-Bonnet N, Bosinger SE, Kelsall BL, Brenchley JM, Ortiz AM.
PMID: 33731830
Mucosal Immunol. 2021 Jul;14(4):937-948. doi: 10.1038/s41385-021-00393-8. Epub 2021 Mar 17.

Microbial translocation contributes to persistent inflammation in both treated and untreated HIV infection. Although translocation is due in part to a disintegration of the intestinal epithelial barrier, there is a bias towards the translocation of Proteobacteria. We hypothesized that...

Cite
Flynn JK, Langner CA, Karmele EP, et al. Luminal microvesicles uniquely influence translocating bacteria after SIV infection. Mucosal Immunol. 2021;14(4):937-948doi: 10.1038/s41385-021-00393-8.
Flynn, J. K., Langner, C. A., Karmele, E. P., Baker, P. J., Pei, L., Gorfu, E. G., Bochart, R. M., Santiana, M., Smelkinson, M. G., Nutman, T. B., Altan-Bonnet, N., Bosinger, S. E., Kelsall, B. L., Brenchley, J. M., & Ortiz, A. M. (2021). Luminal microvesicles uniquely influence translocating bacteria after SIV infection. Mucosal immunology, 14(4), 937-948. https://doi.org/10.1038/s41385-021-00393-8
Flynn, Jacob K, et al. "Luminal microvesicles uniquely influence translocating bacteria after SIV infection." Mucosal immunology vol. 14,4 (2021): 937-948. doi: https://doi.org/10.1038/s41385-021-00393-8
Flynn JK, Langner CA, Karmele EP, Baker PJ, Pei L, Gorfu EG, Bochart RM, Santiana M, Smelkinson MG, Nutman TB, Altan-Bonnet N, Bosinger SE, Kelsall BL, Brenchley JM, Ortiz AM. Luminal microvesicles uniquely influence translocating bacteria after SIV infection. Mucosal Immunol. 2021 Jul;14(4):937-948. doi: 10.1038/s41385-021-00393-8. Epub 2021 Mar 17. PMID: 33731830; PMCID: PMC8225551.
Copy Download .nbib Format: NLM
"Sleep is healthy for your body and brain." Use of student-centered photovoice to explore the translation of sleep promotion at school to sleep behavior at home.

Sleep health

Bird M, McKernan C, Montemurro G, Brown C, Flynn J, Neely KC, Sobierajski F, Sulz L, Storey K.
PMID: 34301526
Sleep Health. 2021 Oct;7(5):588-595. doi: 10.1016/j.sleh.2021.05.006. Epub 2021 Jul 21.

STUDY OBJECTIVES: Schools are an important setting to teach and reinforce positive health behaviors such as sleep, however, research that incorporates the student perspective of school-based sleep promotion initiatives is limited. This study explored student's perceptions of sleep behavior...

Cite
Bird M, McKernan C, Montemurro G, et al. "Sleep is healthy for your body and brain." Use of student-centered photovoice to explore the translation of sleep promotion at school to sleep behavior at home. Sleep Health. 2021;7(5):588-595doi: 10.1016/j.sleh.2021.05.006.
Bird, M., McKernan, C., Montemurro, G., Brown, C., Flynn, J., Neely, K. C., Sobierajski, F., Sulz, L., & Storey, K. (2021). "Sleep is healthy for your body and brain." Use of student-centered photovoice to explore the translation of sleep promotion at school to sleep behavior at home. Sleep health, 7(5), 588-595. https://doi.org/10.1016/j.sleh.2021.05.006
Bird, Melissa, et al. ""Sleep is healthy for your body and brain." Use of student-centered photovoice to explore the translation of sleep promotion at school to sleep behavior at home." Sleep health vol. 7,5 (2021): 588-595. doi: https://doi.org/10.1016/j.sleh.2021.05.006
Bird M, McKernan C, Montemurro G, Brown C, Flynn J, Neely KC, Sobierajski F, Sulz L, Storey K. "Sleep is healthy for your body and brain." Use of student-centered photovoice to explore the translation of sleep promotion at school to sleep behavior at home. Sleep Health. 2021 Oct;7(5):588-595. doi: 10.1016/j.sleh.2021.05.006. Epub 2021 Jul 21. PMID: 34301526.
Copy Download .nbib Format: NLM
Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019.

Open forum infectious diseases

Regan J, Flynn JP, Rosenthal A, Jordan H, Li Y, Chishti R, Giguel F, Corry H, Coxen K, Fajnzylber J, Gillespie E, Kuritzkes DR, Hacohen N, Goldberg MB, Filbin MR, Yu XG, Baden L, Ribeiro RM, Perelson AS, Conway JM, Li JZ.
PMID: 34430669
Open Forum Infect Dis. 2021 Apr 17;8(8):ofab153. doi: 10.1093/ofid/ofab153. eCollection 2021 Aug.

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) kinetics remain understudied, including the impact of remdesivir. In hospitalized individuals, peak sputum viral load occurred in week 2 of symptoms, whereas viremia peaked within 1 week of symptom-onset, suggesting early systemic...

Cite
Regan J, Flynn JP, Rosenthal A, et al. Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infect Dis. 2021;8(8):ofab153doi: 10.1093/ofid/ofab153.
Regan, J., Flynn, J. P., Rosenthal, A., Jordan, H., Li, Y., Chishti, R., Giguel, F., Corry, H., Coxen, K., Fajnzylber, J., Gillespie, E., Kuritzkes, D. R., Hacohen, N., Goldberg, M. B., Filbin, M. R., Yu, X. G., Baden, L., Ribeiro, R. M., Perelson, A. S., Conway, J. M., Li, J. Z. (2021). Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open forum infectious diseases, 8(8), ofab153. https://doi.org/10.1093/ofid/ofab153
Regan, James, et al. "Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019." Open forum infectious diseases vol. 8,8 (2021): ofab153. doi: https://doi.org/10.1093/ofid/ofab153
Regan J, Flynn JP, Rosenthal A, Jordan H, Li Y, Chishti R, Giguel F, Corry H, Coxen K, Fajnzylber J, Gillespie E, Kuritzkes DR, Hacohen N, Goldberg MB, Filbin MR, Yu XG, Baden L, Ribeiro RM, Perelson AS, Conway JM, Li JZ. Viral Load Kinetics of Severe Acute Respiratory Syndrome Coronavirus 2 in Hospitalized Individuals With Coronavirus Disease 2019. Open Forum Infect Dis. 2021 Apr 17;8(8):ofab153. doi: 10.1093/ofid/ofab153. eCollection 2021 Aug. PMID: 34430669; PMCID: PMC8083268.
Copy Download .nbib Format: NLM
Showing 397 to 405 of 405 entries